Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527325) titled 'Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma' on April 7.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: University of California, Irvine

Condition: Melanoma (Skin)

Intervention: Drug: Fianlimab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: April 30, 2026

Target Sample Size: 35

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07527325

Published by HT Digital Content Services with p...